Hansa Medical AB (publ) - Year-End Report 2015
Several significant milestones reached in 2015January – December 2015 in summary – Highlights October – December · Hansa Medical’s shares began trading on Nasdaq Stockholm on November 2, 2015 · Data from the first patient in the ongoing US study with IdeS in highly sensitized patients presented at Hansa Medical’s Capital Markets Day on November 13, 2015, showed that one dose of IdeS effectively inactivates donor specific antibodies · Data published in Journal of Immunology shows that IdeS temporarily can silence B-cells, preventing B-cells from developing into antibody